Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major Histocompatibility Complex (MHC) Class I and II Antigen Presentation (MHC I/II Antigen Presentation)
- Target
- MHC I/II Antigen Presentation
- Molecular classification
- Protein complex, MHC Class I, MHC Class II, Antigen Processing Machinery
01
Overview
Tumor-associated antigen presentation via major histocompatibility complex class I and II molecules is central to anti-tumor immunity. It enables cytotoxic and helper T-cell responses against malignant cells but is frequently targeted by tumors seeking immune escape through loss or alteration of these pathways. Understanding this process informs both prognostic assessment and therapeutic intervention strategies across oncology disciplines.
- Other names
- Tumor-Associated Antigen PresentationT cell antigen presentationHLA antigen presentation
02
Mechanism of action
Checkpoint inhibitors block inhibitory signals, enhancing T cell activation by presented antigens. MHC upregulators (experimental) aim to increase MHC expression and antigen presentation.
03
Biological functions
Antigen processingAntigen presentationT cell activationImmune surveillanceAdaptive immunity
04
Disease associations
CancerAutoimmune diseasesInfectionInflammation
05
Safety considerations
Immune-related adverse events (irAEs) associated with checkpoint inhibitorsOff-target effects of MHC modulatorsPotential for autoimmunity
06
Interacting drugs
Checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4)
2 more in the full profile.
07
Biomarkers
MHC Class I expression levelsMHC Class II expression levelsTumor mutational burden (TMB)Neoantigen loadCD8+ T cell infiltration
Beyond the preview
Go deeper on Major Histocompatibility Complex (MHC) Class I and II Antigen Presentation (MHC I/II Antigen Presentation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Major Histocompatibility Complex (MHC) Class I and II Antigen Presentation (MHC I/II Antigen Presentation).